Bharat Immunologicals and Biologicals Corporation Limited (**BIBCOL**) is a Central Public Sector Undertaking (CPSU) under the administrative control of the **Department of Biotechnology, Ministry of Science and Technology**, Government of India. Established to bolster India’s self-reliance in life-saving immunobiologicals, the company operates a specialized manufacturing base in **Bulandshahr, Uttar Pradesh**. While historically a cornerstone of the **National Immunization Programme**, the company is currently navigating a complex transition involving infrastructure modernization, product diversification, and significant financial restructuring. --- ### **Core Product Portfolio & Revenue Concentration** BIBCOL’s business model is characterized by high dependency on government procurement, with the **Ministry of Health and Family Welfare** serving as its primary client. The company’s operations are classified under a single reporting segment as per **Ind AS 108**. | Segment / Product | FY 2022-23 Revenue (₹ Lakhs) | FY 2021-22 Revenue (₹ Lakhs) | | :--- | :---: | :---: | | **Oral Polio Vaccine (OPV)** | **4,460.88** | **7,834.73** | | **BIBSANIT (Sanitizers)** | **0.02** | **3.52** | | **Zinc Tablets** | **0.00** | **0.00** | | **BIB VIT / Others** | **0.00** | **0.02** | | **Total Segment Revenue** | **4,460.90** | **7,838.27** | **Key Product Categories:** * **Vaccines:** The **Oral Polio Vaccine (OPV)** remains the dominant revenue driver. The company is currently expanding into the **Oral Cholera Vaccine (OCV)** segment. * **Nutraceuticals & Supplements:** Includes **Zinc Dispersible Tablets** (pediatric diarrhea management), **BIB VIT** (multivitamins), and **BIB Sweet** (tabletop sweeteners). * **Healthcare Kits:** Production of **Diarrhea Management Kits** for public health distribution. --- ### **Strategic Modernization & R&D Pipeline** To mitigate its reliance on a single product, BIBCOL is leveraging **Government of India (GoI) grants** to upgrade facilities and enter high-barrier therapeutic segments. | Project Focus | Grant Amount (₹ Lacs) | Status | Strategic Objective | | :--- | :---: | :--- | :--- | | **Oral Polio Vaccine (OPV)** | **476.35** | Under Progress | Process optimization and quality upgrades for the formulation facility. | | **Oral Cholera Vaccine (OCV)** | **617.87** | Under Progress | Establishing R&D and trial production facilities. | | **Plasma Fractionation** | **16.00** | Under Progress | R&D for therapeutic proteins like **Albumin** and **Immunoglobulin**. | **Operational Initiatives:** * **Infrastructure Upgrades:** The company is currently seeking time extensions from the **Department of Biotechnology** to finalize the commissioning of modernized OPV lines. * **Asset Revaluation:** A recent revaluation of land at the **Chola, Bulandshahr** site was conducted, with the surplus credited to the **Revaluation Reserve** to bolster the balance sheet. * **Capital Structure:** As of March 31, 2023, **97.75%** of equity share capital is **dematerialized**, and the company remains listed on the **Bombay Stock Exchange (BSE)**. --- ### **Financial Performance & Capital Management** BIBCOL is currently experiencing severe financial stress, evidenced by a sharp contraction in turnover and widening losses. * **Profitability:** The company reported a **Total Comprehensive Loss** of **₹1,663.88 Lakhs** in FY 2022-23, compared to a loss of **₹875.36 Lakhs** in the previous year. * **Debt Profile:** The company manages a mix of floating and fixed-rate debt. * **Variable Rate Borrowings:** **₹6,554.41 Lakhs** (exposed to interest rate fluctuations). * **Fixed Rate Borrowings:** **₹467.40 Lakhs**. * **Revival Strategy:** A **Financial Revival Package** is currently being processed through the Ministry of Science & Technology to restore industrial viability and address **negative net worth**. --- ### **Critical Risk Factors & Material Uncertainties** The company’s independent auditors have issued an **Adverse Opinion** for FY 2022-23, citing a **Material Uncertainty Related to Going Concern**. **1. Operational & Market Risks:** * **Product Concentration:** Heavy reliance on OPV and the **perpetual import of bulk vaccine** creates significant supply chain and sovereign risk. * **Procurement Shifts:** The Ministry of Health is moving away from **nomination-based orders**, and the removal of **PSU price preferences** has intensified competition from private players. * **Liquidity Crisis:** Current liabilities exceed total assets, and the company has defaulted on a **₹550.00 Lakhs** gratuity liability demanded by LIC. **2. Audit Qualifications & Internal Control Deficiencies:** * **Asset Verification:** No **Fixed Asset Register** was provided for audit; title deeds for **60 acres** of land (Chola and Ganger sites) were not produced. * **Inventory & Receivables:** Lack of movement registers and valuation records. Furthermore, **₹645.42 Lakhs** in late delivery charges from 2013-15 are considered doubtful, with no balance confirmations available. * **Grant Mismanagement:** Auditors noted that project funds are often used **interchangeably**, violating specific sanction orders from the GoI. **3. Regulatory & Legal Exposure:** * **Non-compliance with Ind AS:** Significant deviations from **Ind AS-16** (PPE), **Ind AS-36** (Impairment), and **Ind AS-116** (Leases). * **Land Disputes:** **1.5 acres** of land were acquired by NHAI without clear financial accounting; additionally, **13.9 acres** were leased to NIPGR on an unregistered deed at a nominal, non-commercial rate of **₹10,000/year**. * **Contingent Liabilities:** Includes pending staff litigations and undisclosed tax disputes that could further impact the company's solvency. --- ### **Investment Summary** BIBCOL represents a high-risk turnaround prospect. While it possesses a strategic manufacturing footprint and enjoys continued support from the **Ministry of Science and Technology** through grants and a pending **Financial Revival Package**, its current state is hampered by **negative net worth**, severe **audit qualifications**, and a lack of internal financial controls. The successful commissioning of the **Oral Cholera Vaccine** and **Plasma Fractionation** facilities are critical milestones required to pivot the company away from its current dependency on the declining OPV market.